Skip to main content
Valneva SE logo

Valneva SE — Investor Relations & Filings

Ticker · VLA ISIN · FR0004056851 LEI · 969500DIVIP5VKNW4948 PA Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2026-01-09 Regulatory Filings
Country FR France
Listing PA VLA

About Valneva SE

https://valneva.com/

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. The company has leveraged its expertise to commercialize three vaccines, including a single-shot vaccine for chikungunya. Its research and development pipeline features a broad range of vaccine candidates, including those targeting Lyme disease, Shigella, and Zika.

Recent filings

Filing Released Lang Actions
Valneva to Meet with Investors during the J.P. Morgan Healthcare Conference
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Valneva's management team will be attending and meeting with investors at the J.P. Morgan Healthcare Conference. It does not contain financial results, a report, or a specific regulatory filing requirement, but rather serves as a general corporate announcement regarding investor relations activities. As it does not fit into specific categories like earnings releases or reports, it is classified as a general regulatory filing/announcement.
2026-01-09 English
Valneva SE - Declaration of voting rights - December 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal declaration of the total number of shares and voting rights for Valneva as of December 31, 2025. It explicitly mentions 'Declaration of shares and voting rights' and provides a table detailing the number of shares, theoretical voting rights, and net voting rights. This type of disclosure is a standard regulatory requirement in France (AMF regulations) for listed companies to inform the market about their capital structure and voting rights, which falls under the 'Declaration of Voting Results & Voting Rights Announcements' category.
2026-01-08 English
Déclaration d'actions et de droits de vote de la société Valneva SE - décembre 2025
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is a formal declaration of the total number of shares and voting rights for Valneva as of December 31, 2025. This type of filing is a standard regulatory requirement in France (AMF regulations) to provide transparency regarding share capital and voting rights, which is essential for shareholders to calculate threshold crossings. It does not fit into 'Major Shareholding Notification' (which is for specific investors) or 'Share Issue' (which is for specific corporate actions), but rather serves as a periodic regulatory disclosure of capital structure. Therefore, it is best classified as a Regulatory Filing (RNS).
2026-01-08 French
6-K
Regulatory Filings
2025-12-31 English
Valneva et le Serum Institute of India annoncent la fin de leur accord de licence pour le vaccin contre le chikungunya
Regulatory Filings Classification · 95% confidence The document is a press release issued by Valneva SE announcing the termination of a licensing agreement with the Serum Institute of India. It follows the standard format of a corporate press release, including contact information for media and investors, a disclaimer regarding forward-looking statements, and background information on the companies involved. Since it is a general regulatory announcement regarding corporate strategy and partnerships that does not fit into more specific categories like M&A (which usually implies a takeover or merger) or financial results, it is classified as a Regulatory Filing (RNS).
2025-12-31 French
Valneva and Serum Institute of India Announce Discontinuation of Chikungunya Vaccine License Agreement
Regulatory Filings Classification · 95% confidence The document is a press release announcing the discontinuation of a license agreement between Valneva SE and the Serum Institute of India regarding a chikungunya vaccine. This type of corporate announcement regarding strategic partnerships and licensing agreements does not fit into specific categories like financial reports, dividends, or director dealings. Therefore, it is classified as a general regulatory announcement (RNS).
2025-12-31 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.